Cyclin-dependent kinases 4/6 (CDK4/6) inhibitors such as palbociclib are approved for the treatment of metastatic estrogen receptor–positive (ER+) breast cancer in combination with endocrine therapies and significantly improve outcomes in patients with this disease. The gene discussed is CDK4; the disease is breast cancer.